Target intelligence / Profile preview

Histone H3.2 (H3C15)

Target
H3C15
Molecular classification
Histone, Chromatin protein, Structural protein
01

Overview

Histone H3.2 (H3C15) is a replication-dependent core histone protein encoded by an intronless gene (H3C15/HIST2H3A) located in a histone gene cluster on human chromosome 1[1][2][3][8][9]. It is one of four core histones (H2A, H2B, H3, H4) that together form the nucleosome, the basic structural unit of eukaryotic chromatin, with approximately 146 base pairs of DNA wrapped around a histone octamer. Histone H3.2 plays a central role in the organization and compaction of DNA, limiting accessibility to genetic material. The molecule is subject to numerous post-translational modifications that constitute the 'histone code', influencing DNA-related processes such as transcription, DNA repair, replication, and chromosome stability. This particular variant is not a common direct drug target, but global or site-specific modifications of histone H3 are significant in research on gene regulation and diseases associated with epigenetic dysregulation[1][2][3][9].

Other names
HIST2H3AH3F2H3FMHIST2H3CHIST2H3DH3/nH3/oH3C13H3C14histone cluster 2 H3 family member ahistone H3/mhistone H3/oH3-clustered histone 13H3-clustered histone 14H3-clustered histone 15histone 2 H3aH3a
02

Mechanism of action

Not directly drug-targeted; general histone-modifying agents alter histone code to modulate gene expression

03

Biological functions

Chromatin structure organizationRegulation of transcriptionDNA repairDNA replicationChromosomal stability
04

Disease associations

Progeroid syndromes (e.g., Hutchinson-Gilford Progeria Syndrome)Cancer (in relation to global histone modifications)Other epigenetic disorders
05

Safety considerations

Non-specific targeting of histones or chromatin-modifying enzymes may lead to widespread gene expression changes and toxicity
06

Interacting drugs

None that directly target this histone variant (as of available data); histone deacetylase inhibitors and general chromatin-modifying agents may affect function indirectly
07

Biomarkers

Global levels or specific post-translational modifications (e.g., methylation, acetylation) of histone H3 variants are used as biomarkers in cancers and epigenetic studies

Beyond the preview

Go deeper on Histone H3.2 (H3C15).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone H3.2 (H3C15).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call